GSK, Kaleo Scale Back Orange Book IP In FTC Campaign
The Federal Trade Commission's push to stop drugmakers from artificially extending their exclusivity period by misusing a U.S. Food and Drug Administration database has resulted in GlaxoSmithKline, Kaleo and Impax Laboratories...To view the full article, register now.
Already a subscriber? Click here to view full article